Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087950 | 0.86 | MAOB (1.00) | MAOBL3MBTL1MAOAPARP15PARP14 | |
| SCHEMBL2087136 | 0.83 | MAOB (0.64) | MAOBL3MBTL1GAAMAOAPARP15 | |
| SCHEMBL18477946 | 0.80 | MAOB (0.73) | MAOBL3MBTL1GAAMAOAMAPT | |
| SCHEMBL2086520 | 0.80 | FFAR1 (0.50) | MAOBL3MBTL1GAAPARP15PARP14 | |
| SCHEMBL15079868 | 0.80 | CYP1A2 (0.53) | MAOBL3MBTL1PARP15PARP14PARP10 | |
| SCHEMBL6957386 | 0.80 | MAOB (0.71) | MAOBL3MBTL1GAAMAPTALDH1A1 | |
| SCHEMBL15079383 | 0.79 | MAOB (0.51) | MAOBL3MBTL1GAAPARP15PARP14 | |
| SCHEMBL5289695 | 0.79 | L3MBTL1 (0.75) | MAOBL3MBTL1GAAMAOAPARP10 | |
| SCHEMBL832653 | 0.78 | TRPV1 (0.54) | MAOBL3MBTL1PARP15PARP14PARP10 | |
| SCHEMBL834525 | 0.78 | L3MBTL1 (0.88) | MAOBL3MBTL1GAAMAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | disclosed |
| US-7863475-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7547802-B2 | 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-06-16 | — | — | US | disclosed |
| US-7329782-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885L3MBTL1 985/4885GAA 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.